Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$18.99 - $33.2 $13.1 Million - $22.9 Million
-690,344 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$19.41 - $26.0 $236,142 - $316,316
12,166 Added 1.79%
690,344 $15.8 Million
Q3 2020

Nov 16, 2020

SELL
$24.69 - $31.6 $1.75 Million - $2.24 Million
-70,740 Reduced 9.45%
678,178 $17.1 Million
Q2 2020

Aug 14, 2020

SELL
$5.2 - $29.12 $3.85 Million - $21.5 Million
-739,624 Reduced 49.69%
748,918 $20.9 Million
Q1 2020

May 15, 2020

SELL
$4.28 - $12.11 $71,946 - $203,569
-16,810 Reduced 1.12%
1,488,542 $8.66 Million
Q4 2019

Feb 13, 2020

BUY
$7.95 - $12.27 $644,530 - $994,765
81,073 Added 5.69%
1,505,352 $16.4 Million
Q3 2019

Nov 13, 2019

BUY
$12.44 - $17.48 $109,894 - $154,418
8,834 Added 0.62%
1,424,279 $18.2 Million
Q2 2019

Aug 13, 2019

SELL
$14.51 - $19.71 $402,667 - $546,972
-27,751 Reduced 1.92%
1,415,445 $24 Million
Q1 2019

May 14, 2019

BUY
$11.11 - $25.6 $8.5 Million - $19.6 Million
764,646 Added 112.69%
1,443,196 $25.9 Million
Q4 2018

Feb 13, 2019

BUY
$11.75 - $21.42 $116,442 - $212,272
9,910 Added 1.48%
678,550 $8.62 Million
Q3 2018

Nov 14, 2018

SELL
$19.26 - $23.46 $72,783 - $88,655
-3,779 Reduced 0.56%
668,640 $14.3 Million
Q2 2018

Jul 30, 2018

BUY
$19.78 - $24.67 $520,411 - $649,067
26,310 Added 4.07%
672,419 $13.9 Million
Q1 2018

May 07, 2018

BUY
$18.89 - $32.46 $256,677 - $441,066
13,588 Added 2.15%
646,109 $16.3 Million
Q4 2017

Feb 07, 2018

BUY
$16.19 - $20.3 $707,859 - $887,556
43,722 Added 7.43%
632,521 $12 Million
Q3 2017

Nov 07, 2017

BUY
$15.52 - $18.94 $9.14 Million - $11.2 Million
588,799
588,799 $10.9 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $224M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Hood River Capital Management LLC Portfolio

Follow Hood River Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hood River Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hood River Capital Management LLC with notifications on news.